Lower Within-Subject Variability of Insulin Detemir in Comparison to NPH Insulin and Insulin Glargine in People With Type 1 Diabetes
-
- Tim Heise
- Profil Institut für Stoffwechselforschung, Neuss, Germany
-
- Leszek Nosek
- Profil Institut für Stoffwechselforschung, Neuss, Germany
-
- Birgitte Biilmann Rønn
- Novo Nordisk, Bagsvaerd, Denmark
-
- Lars Endahl
- Novo Nordisk, Bagsvaerd, Denmark
-
- Lutz Heinemann
- Profil Institut für Stoffwechselforschung, Neuss, Germany
-
- Christoph Kapitza
- Profil Institut für Stoffwechselforschung, Neuss, Germany
-
- Eberhard Draeger
- Novo Nordisk, Bagsvaerd, Denmark
抄録
<jats:p>The aim of this randomized double-blind study was to compare the within-subject variability of the glucose-lowering effect of a novel insulin analog, insulin detemir, with that of insulin glargine and NPH insulin in people with type 1 diabetes. Fifty-four subjects (32 males and 22 females, age 38 ± 10 years [mean ± SD], BMI 24 ± 2 kg/m2, HbA1c 7.5 ± 1.2%, diabetes duration 18 ± 9 years) participated in this parallel group comparison. Each subject received four single subcutaneous doses of 0.4 units/kg of either insulin detemir (n = 18), insulin glargine (n = 16), or human NPH insulin (n = 17) under euglycemic glucose clamp conditions (target blood glucose concentration 5.5 mmol/l) on four identical study days. The pharmacodynamic (glucose infusion rates [GIRs]) and pharmacokinetic (serum concentrations of insulin detemir, human insulin, and insulin glargine) properties of the basal insulin preparations were recorded for 24 h postdosing. Insulin detemir was associated with significantly less within-subject variability than both NPH insulin and insulin glargine, as assessed by the coefficient of variation (CV) for the pharmacodynamic end points studied [GIR-AUC(0–12 h) 27% (detemir) vs. 59% (NPH) vs. 46% (glargine); GIR-AUC(0–24 h) 27 vs. 68 vs. 48%; GIRmax 23 vs. 46 vs. 36%; P < 0.001 for all comparisons]. Insulin detemir also provided less within-subject variability in the pharmacokinetic end points: maximal concentration (Cmax) 18 vs. 24 vs. 34%; INS-AUC(0–∞) 14 vs. 28 vs. 33%. The results suggest that insulin detemir has a significantly more predictable glucose-lowering effect than both NPH insulin and insulin glargine.</jats:p>
収録刊行物
-
- Diabetes
-
Diabetes 53 (6), 1614-1620, 2004-06-01
American Diabetes Association
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1362825894785969792
-
- NII論文ID
- 30026264458
-
- ISSN
- 1939327X
- 00121797
-
- データソース種別
-
- Crossref
- CiNii Articles